BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Benesic A, Leitl A, Gerbes AL. Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut 2016;65:1555-63. [PMID: 26045135 DOI: 10.1136/gutjnl-2015-309528] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Weber S, Benesic A, Gerbes AL. Further evidence for the hepatotoxic potential of metamizole. Br J Clin Pharmacol 2021;87:1587-8. [PMID: 32696537 DOI: 10.1111/bcp.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Benesic A, Rotter I, Dragoi D, Weber S, Leitl A, Buchholtz ML, Gerbes AL. Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol 2018;16:1488-1494.e5. [PMID: 29723689 DOI: 10.1016/j.cgh.2018.04.049] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
3 Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
4 Benesic A, Jalal K, Gerbes AL. Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences 2019;171:296-302. [DOI: 10.1093/toxsci/kfz156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Kulkeaw K, Pengsart W. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases. Micromachines (Basel) 2021;12:842. [PMID: 34357252 DOI: 10.3390/mi12070842] [Reference Citation Analysis]
6 Antoine DJ, Dear JW. Transformative biomarkers for drug-induced liver injury: are we there yet? Biomarkers in Medicine 2017;11:103-6. [DOI: 10.2217/bmm-2016-0338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Le Daré B, Ferron PJ, Gicquel T. [Once upon a time the hepatotoxicity…]. Med Sci (Paris) 2021;37:235-41. [PMID: 33739270 DOI: 10.1051/medsci/2021009] [Reference Citation Analysis]
8 Kaliyaperumal K, Grove JI, Delahay RM, Griffiths WJH, Duckworth A, Aithal GP. Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications.J Hepatol. 2018;69:948-957. [PMID: 29792895 DOI: 10.1016/j.jhep.2018.05.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
9 Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol 2019;10:730. [PMID: 31396080 DOI: 10.3389/fphar.2019.00730] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
10 He Y, Li S, Tang D, Peng Y, Meng J, Peng S, Deng Z, Qiu S, Liao X, Chen H, Tu S, Tao L, Peng Z, Yang H. Circulating Peroxiredoxin-1 is a novel damage-associated molecular pattern and aggravates acute liver injury via promoting inflammation. Free Radic Biol Med 2019;137:24-36. [PMID: 30991142 DOI: 10.1016/j.freeradbiomed.2019.04.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
11 Weber S, Benesic A, Neumann J, Gerbes AL. Liver Injury Associated with Metamizole Exposure: Features of an Underestimated Adverse Event. Drug Saf 2021;44:669-80. [PMID: 33638811 DOI: 10.1007/s40264-021-01049-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hammond S, Thomson PJ, Ogese MO, Naisbitt DJ. T-Cell Activation by Low Molecular Weight Drugs and Factors That Influence Susceptibility to Drug Hypersensitivity. Chem Res Toxicol 2020;33:77-94. [PMID: 31687800 DOI: 10.1021/acs.chemrestox.9b00327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154-64. [PMID: 28341748 DOI: 10.1136/gutjnl-2016-313369] [Cited by in Crossref: 196] [Cited by in F6Publishing: 176] [Article Influence: 39.2] [Reference Citation Analysis]
14 Benesic A, Gerbes AL. Herbal tea and liver injury - Tea extract or comedication can make a difference. J Hepatol 2018;69:547-8. [PMID: 29776714 DOI: 10.1016/j.jhep.2018.03.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Segovia-zafra A, Di Zeo-sánchez DE, López-gómez C, Pérez-valdés Z, García-fuentes E, Andrade RJ, Lucena MI, Villanueva-paz M. Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B 2021;11:3685-726. [DOI: 10.1016/j.apsb.2021.11.013] [Reference Citation Analysis]
16 Tillmann HL, Barnhart HX, Serrano J, Rockey DC. Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease. Curr Hepatol Rep 2018;17:276-82. [PMID: 30766772 DOI: 10.1007/s11901-018-0416-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Woo SM, Davis WD, Aggarwal S, Clinton JW, Kiparizoska S, Lewis JH. Herbal and dietary supplement induced liver injury: Highlights from the recent literature. World J Hepatol 2021; 13(9): 1019-1041 [PMID: 34630872 DOI: 10.4254/wjh.v13.i9.1019] [Reference Citation Analysis]
18 Freeman E, Roberts SK. Drug-induced liver injury caused by herbal and dietary supplements: where to next? Med J Aust 2021;215:259-60. [PMID: 34386975 DOI: 10.5694/mja2.51223] [Reference Citation Analysis]
19 Williams DP. Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery. Philos Trans R Soc Lond B Biol Sci 2018;373:20170228. [PMID: 29786562 DOI: 10.1098/rstb.2017.0228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
20 Weber S, Benesic A, Rotter I, Gerbes AL. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int 2019;39:1906-17. [PMID: 31319011 DOI: 10.1111/liv.14195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
21 Meunier L, Larrey D. Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. Front Pharmacol 2019;10:1482. [PMID: 31920666 DOI: 10.3389/fphar.2019.01482] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
22 Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update.Arch Toxicol. 2020;94:3381-3407. [PMID: 32852569 DOI: 10.1007/s00204-020-02885-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
23 Hammond S, Thomson P, Meng X, Naisbitt D. In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs. Front Immunol 2021;12:630530. [PMID: 33927714 DOI: 10.3389/fimmu.2021.630530] [Reference Citation Analysis]
24 Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A. Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. Drug Saf 2021;44:619-34. [PMID: 33725335 DOI: 10.1007/s40264-021-01051-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, Guillouzo A, Hewitt PG, Ingelman-sundberg M, Jensen KG, Juhila S, Klingmüller U, Labbe G, Liguori MJ, Lovatt CA, Morgan P, Naisbitt DJ, Pieters RHH, Snoeys J, van de Water B, Williams DP, Park BK. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov 2020;19:131-48. [DOI: 10.1038/s41573-019-0048-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
26 Dragoi D, Benesic A, Pichler G, Kulak NA, Bartsch HS, Gerbes AL. Proteomics Analysis of Monocyte-Derived Hepatocyte-Like Cells Identifies Integrin Beta 3 as a Specific Biomarker for Drug-Induced Liver Injury by Diclofenac. Front Pharmacol 2018;9:699. [PMID: 30022949 DOI: 10.3389/fphar.2018.00699] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
27 Talaat N, Tillmann HL. Injury pattern recognition to discriminate competing causes of liver injury. Liver Int 2019;39:821-5. [PMID: 30703293 DOI: 10.1111/liv.14056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
28 Wang Z, Li W, Jing H, Ding M, Fu G, Yuan T, Huang W, Dai M, Tang D, Zeng M, Chen Y, Zhang H, Zhu X, Peng Y, Li Q, Yu WF, Yan HX, Zhai B. Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening. Theranostics 2019;9:6690-705. [PMID: 31588244 DOI: 10.7150/thno.34520] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
29 Inoue T, Iwazaki N, Araki T, Hitotsumachi H. Human-Induced Pluripotent Stem Cell-Derived Hepatocytes and their Culturing Methods to Maintain Liver Functions for Pharmacokinetics and Safety Evaluation of Pharmaceuticals. Curr Pharm Biotechnol 2020;21:773-9. [PMID: 32003687 DOI: 10.2174/1389201021666200131123524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]